Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Condition: Uveal Melanoma Interventions: Drug: ADI PEG20; Drug: Nivolumab; Drug: Ipilimumab Sponsor: Memorial Sloan Kettering Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Eye Cancers | Immunotherapy | Melanoma | Research | Skin Cancer | Study | Uveal Melanoma | Yervoy